利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

14 条记录 (耗时 0.035 秒)

    Sustained release intraocular implants and related methods
    4.
    发明申请
    Sustained release intraocular implants and related methods 有权
    持续释放眼内植入物及相关方法

    公开(公告)号：US20050244468A1

    公开(公告)日：2005-11-03

    申请号：US10837356

    申请日：2004-04-30

    申请人： Glenn Huang ,  Thierry Nivaggioli

    发明人： Glenn Huang ,  Thierry Nivaggioli

    IPC分类号： A61K9/00 ,  A61K31/00 ,  A61K31/573 ,  A61K45/06 ,  A61F2/00

    CPC分类号： A61K9/0051 ,  A61K9/0092 ,  A61K31/573 ,  A61K31/58 ,  A61K45/06 ,  A61K2300/00

    摘要： Biocompatible intraocular implants include a steroid and a polymer associated with each other to facilitate release of the steroid into an eye for a period of time greater than about two months. The steroid may be associated with a biodegradable polymer matrix, such as a matrix of a two biodegradable polymers. Or, the steroid may be associated with a polymeric coating having one or more openings effective to permit the steroid to be released into an external environment. The implants may be placed in an eye to treat one or more ocular conditions. The steroid is released from the implant for more than about two months, and may be release for more than several years.

    摘要翻译： 生物相容性眼内植入物包括彼此相关的类固醇和聚合物，以促进类固醇进入眼睛大于约两个月的时间。 类固醇可以与可生物降解的聚合物基质相关联，例如两种可生物降解聚合物的基质。 或者，类固醇可以与具有一个或多个开口有效以允许类固醇释放到外部环境中的聚合物涂层相关联。 植入物可以放置在眼睛中以治疗一种或多种眼睛状况。 类固醇从植入物中释放超过约两个月，可能会释放超过几年。

    Sustained release intraocular implants and methods for treating ocular neuropathies
    5.
    发明申请
    Sustained release intraocular implants and methods for treating ocular neuropathies 审中-公开
    持续释放眼内植入物和治疗眼神经病变的方法

    公开(公告)号：US20050244458A1

    公开(公告)日：2005-11-03

    申请号：US10836880

    申请日：2004-04-30

    申请人： Glenn Huang ,  Thierry Nivaggioli

    发明人： Glenn Huang ,  Thierry Nivaggioli

    IPC分类号： A61K9/00 ,  A61K31/537 ,  A61K31/138

    CPC分类号： A61K9/0051 ,  A61K31/5377

    摘要： Biocompatible intraocular implants include a beta adrenergic receptor antagonist and a polymer associated with the beta adrenergic receptor antagonist to facilitate release of the beta adrenergic receptor antagonist into an eye for an extended period of time. The beta adrenergic receptor antagonist may be associated with a biodegradable polymer matrix, such as a matrix of a two biodegradable polymers. The implants may be placed in an eye to treat one or more ocular conditions, such as an ocular neuropathies, for example, various forms of glaucoma.

    摘要翻译： 生物相容性眼内植入物包括β-肾上腺素能受体拮抗剂和与β-肾上腺素能受体拮抗剂相关的聚合物，以促进β肾上腺素能受体拮抗剂延长一段时间的眼睛释放。 β肾上腺素能受体拮抗剂可以与可生物降解的聚合物基质例如两种可生物降解聚合物的基质相关联。 植入物可以放置在眼睛中以治疗一种或多种眼部病症，例如眼部神经病，例如各种形式的青光眼。

    Sustained release intraocular implants and methods for preventing retinal dysfunction
    7.
    发明申请
    Sustained release intraocular implants and methods for preventing retinal dysfunction 审中-公开
    持续释放眼内植入物和预防视网膜功能障碍的方法

    公开(公告)号：US20050244506A1

    公开(公告)日：2005-11-03

    申请号：US11118519

    申请日：2005-04-29

    申请人： James Burke ,  Patrick Hughes ,  Werhner Orilla ,  Ton Lin ,  Maria Escobar ,  Glenn Huang ,  Kai-Ming Zhang ,  Larry Wheeler ,  Rosy Donn

    发明人： James Burke ,  Patrick Hughes ,  Werhner Orilla ,  Ton Lin ,  Maria Escobar ,  Glenn Huang ,  Kai-Ming Zhang ,  Larry Wheeler ,  Rosy Donn

    IPC分类号： A61F2/02 ,  A61K9/00 ,  A61K9/14 ,  A61K31/498

    CPC分类号： A61K31/498 ,  A61K9/0051 ,  A61K47/34

    摘要： Biocompatible intraocular microspheres and implants include an alpha-2 adrenergic receptor agonist and a polymer associated with the alpha-2 adrenergic receptor agonist to facilitate release of the alpha-2 adrenergic receptor agonist into an eye for an extended period of time. The alpha-2 adrenergic receptor agonist may be associated with a biodegradable polymer matrix, such as a matrix of a two biodegradable polymers. The implants may be placed in an eye to treat or to prevent the occurrence of one or more ocular conditions, to reduce one or more symptoms of an ocular condition, such as an ocular neurosensory disorder and the like, to enhance normal retinal function and/or to lower intraocular pressure.

    摘要翻译： 生物相容的眼内微球和植入物包括α-2肾上腺素能受体激动剂和与α-2肾上腺素能受体激动剂相关的聚合物，以促进α-2肾上腺素能受体激动剂延长一段时间的眼睛释放。 α-2肾上腺素能受体激动剂可以与可生物降解的聚合物基质例如两种可生物降解的聚合物的基质相关联。 植入物可以放置在眼睛中以治疗或防止一种或多种眼部病症的发生，以减少眼部疾病如眼部神经感觉障碍等的一种或多种症状，以增强正常的视网膜功能和/ 或降低眼内压。

    Sustained release intraocular implants and methods for preventing retinal dysfunction
    10.
    发明申请
    Sustained release intraocular implants and methods for preventing retinal dysfunction 有权
    持续释放眼内植入物和预防视网膜功能障碍的方法

    公开(公告)号：US20050244479A1

    公开(公告)日：2005-11-03

    申请号：US10837143

    申请日：2004-04-30

    申请人： Glenn Huang ,  James Burke ,  Patrick Hughes ,  Kai-Ming Zhang ,  Ton Lin ,  Larry Wheeler ,  Rosy Donn

    发明人： Glenn Huang ,  James Burke ,  Patrick Hughes ,  Kai-Ming Zhang ,  Ton Lin ,  Larry Wheeler ,  Rosy Donn

    IPC分类号： A61F2/02 ,  A61K9/00 ,  A61K9/14 ,  A61K31/498

    CPC分类号： A61K31/498 ,  A61K9/0051 ,  A61K47/34

    摘要： Biocompatible intraocular implants include an alpha-2 adrenergic receptor agonist and a polymer associated with the alpha-2 adrenergic receptor agonist to facilitate release of the alpha-2 adrenergic receptor agonist into an eye for an extended period of time. The alpha-2 adrenergic receptor agonist may be associated with a biodegradable polymer matrix, such as a matrix of a two biodegradable polymers. The implants may be placed in an eye to prevent the occurrence of one or more ocular conditions, or to reduce one or more symptoms of an ocular condition, such as an ocular neurosensory disorder and the like.

    摘要翻译： 生物相容性眼内植入物包括α-2肾上腺素能受体激动剂和与α-2肾上腺素能受体激动剂相关的聚合物，以促进α-2肾上腺素能受体激动剂延长一段时间的眼睛释放。 α-2肾上腺素能受体激动剂可以与可生物降解的聚合物基质例如两种可生物降解的聚合物的基质相关联。 植入物可以放置在眼睛中以防止发生一种或多种眼部病症，或者减少眼部疾病如眼睛神经感觉障碍等的一种或多种症状。